The incidence of nephrogenic systemic fibrosis in subjects receiving gadoversetamide for cardiovascular magnetic resonance

The incidence of nephrogenic systemic fibrosis in subjects receiving gadoversetamide for cardiovascular magnetic resonance

Background Since 2006, the US Food and Drug Administration (FDA) has recommended restricting gadolinium based contrast agents (GBCAs) for magnetic resonance in patients with renal impairment due to an association of GBCA use with nephrogenic systemic fibrosis (NSF). [...] hospital policies vary in r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cardiovascular magnetic resonance 2012-02, Vol.14 (S1), p.P48-P48, Article P48
Hauptverfasser: Crowley, Anna Lisa, Kim, Han W, Parker, Michele, Spatz, Deneen, Hayes, Brenda, Bhatti, Lubna, Jensen, Christoph J, Ngo, Jessica, Papalas, John A, Pun, Patrick, Middleton, John P, Judd, Robert M, Kim, Raymond J
Format: Artikel
Sprache:eng
Schlagworte:
Confidence intervals
Kidney diseases
Poster Presentation
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Since 2006, the US Food and Drug Administration (FDA) has recommended restricting gadolinium based contrast agents (GBCAs) for magnetic resonance in patients with renal impairment due to an association of GBCA use with nephrogenic systemic fibrosis (NSF). [...] hospital policies vary in renal impairment screening criteria and restrictions for both agent-specific and GFR cut-off values for GBCA use.
ISSN:1532-429X
1097-6647
1532-429X
DOI:10.1186/1532-429X-14-S1-P48